Showing results (611-620 of 624) with videos related to

Sort By:
Pageof 63
Blood|August 18, 2023
Genome-wide transcription factor-binding maps reveal cell-specific changes in the regulatory architecture of human HSPCsShruthi Subramanian, Julie A I Thoms, Yizhou Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2019
Targeted Therapy in Advanced Melanoma With Rare BRAF MutationsChristian Menzer, Alexander M Menzies, Matteo S Carlino, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome databaseChristian Menzer, Susanne Dugas-Breit, Martin Dugas, et al.
Cancers|July 20, 2021
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic MetastasisElias A T Koch, Anne Petzold, Anja Wessely, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2025
Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patientsSelma Ugurel, Nessr Abu Rached, Thilo Gambichler, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2021
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionSarah Knispel, Maximilian Gassenmaier, Alexander M Menzies, et al.
The Medical Journal of Australia|May 2, 2021
Australia in 2030: what is our path to health for all?Kathryn Backholer, Fran Baum, Summer M Finlay, et al.
Blood|May 6, 2020
The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1Catherine L Carmichael, Jueqiong Wang, Thao Nguyen, et al.
Cell Reports|July 21, 2017
Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic SyndromesAshwin Unnikrishnan, Elli Papaemmanuil, Dominik Beck, et al.
The Lancet. Oncology|December 3, 2014
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort studyEmilie Lalonde, Adrian S Ishkanian, Jenna Sykes, et al.
Pageof 63